Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 460
Filtrar
1.
Vet Med Sci ; 10(3): e1432, 2024 05.
Artículo en Inglés | MEDLINE | ID: mdl-38527006

RESUMEN

BACKGROUND: Trichomonas gallinae is a parasite that causes canker and severe loss and death, especially in young pigeons. Metronidazole (MTZ) is the recommended drug for treating avian trichomoniasis. Due to drug resistance, non-chemical alternatives, such as medicinal plant extracts, are also considered possible therapies for this disease. OBJECTIVES: This study compares the antitrichomonal effects of MTZ with extracts of Camellia sinensis and Ziziphus vulgaris on T. gallinae in vitro. METHODS: Samples of T. gallinae were taken from infected pigeons. Multi-well plates with different concentrations (5, 10, 25, 50 and 100 µg/mL) of plant extracts were used for the in vitro study. RESULTS: The minimum inhibitory concentration (MIC) of C. sinensis extract was 25 µg/mL over 24 h, compared to 50 µg/mL for MTZ. The MIC value of the Z. vulgaris extracts was 50 µg/mL. CONCLUSIONS: The results suggest that the extracts of Z. vulgaris and C. sinensis, as potential natural agents, could have anti-avian trichomoniasis properties. This study also shows that MTZ, C. sinensis and Z. vulgaris are equally effective in preventing the growth of T. gallinae trophozoites in the culture.


Asunto(s)
Camellia sinensis , Tricomoniasis , Trichomonas , Ziziphus , Animales , Tricomoniasis/tratamiento farmacológico , Tricomoniasis/veterinaria , Antitricomonas/farmacología , Antitricomonas/uso terapéutico , Metronidazol/farmacología , Metronidazol/uso terapéutico , Columbidae
2.
Ann Parasitol ; 68(1): 151-157, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35491905

RESUMEN

In recent years, increasing attention has been paid in veterinary medicine to find novel natural resources to reduce the use of synthetic drugs, avoid side effects, and for better compliance of the animals' owners. Metronidazole has been used for many years in the treatment of birds' trichomonosis. Carvacrol is a terpenoid and several biologic activities was attributed to it. The present study developed and characterized a carvacrol nanoemulsion (NanoCAV) and investigated its antitrichomonal activity on Trichomonas gallinae, the causative agent of pigeon trichomonosis, under in vitro condition and compared it with carvacrol (CAV) and the standard antitrichomonal dug, metronidazole (MTZ). Additionally, cytotoxicity of the developed formulation to the fibroblast cell line was evaluated. The NanoCAV mean size and surface charge were 80.5 nm and -31.2 mv, respectively. No significant cytotoxicity was observed for the NanoCAV. Incorporation efficiency of NanoCAV was measured as 75%. Results of antitrichomonal activity assay showed 12 h fifty percent lethal concentrations of 0.39 and 0.27 µg/ml for CAV and NanoCAV, respectively. The NanoCAV based on in vitro activity and low cytotoxicity, can be further studied for its efficacy and safety profile in the pigeons.


Asunto(s)
Enfermedades de las Aves , Tricomoniasis , Trichomonas , Animales , Antitricomonas/farmacología , Antitricomonas/uso terapéutico , Columbidae , Cimenos , Metronidazol/farmacología , Metronidazol/uso terapéutico , Protaminas , Tricomoniasis/veterinaria
3.
BMC Complement Med Ther ; 21(1): 229, 2021 Sep 13.
Artículo en Inglés | MEDLINE | ID: mdl-34517859

RESUMEN

BACKGROUND: We previously reported that the tomato glycoalkaloid tomatine inhibited the growth of Trichomonas vaginalis strain G3, Tritrichomonas foetus strain D1, and Tritrichomonas foetus-like strain C1 that cause disease in humans and farm and domesticated animals. The increasing prevalence of antibiotic resistance requires development of new tools to enhance or replace medicinal antibiotics. METHODS: Wild tomato plants were harvested and divided into leaves, stems, and fruit of different colors: green, yellow, and red. Samples were freeze dried and ground with a handheld mill. The resulting powders were evaluated for their potential anti-microbial effects on protozoan parasites, bacteria, and fungi. A concentration of 0.02% (w/v) was used for the inhibition of protozoan parasites. A high concentration of 10% (w/v) solution was tested for bacteria and fungi as an initial screen to evaluate potential anti-microbial activity and results using this high concentration limits its clinical relevance. RESULTS: Natural powders derived from various parts of tomato plants were all effective in inhibiting the growth of the three trichomonads to varying degrees. Test samples from leaves, stems, and immature 'green' tomato peels and fruit, all containing tomatine, were more effective as an inhibitor of the D1 strain than those prepared from yellow and red tomato peels which lack tomatine. Chlorogenic acid and quercetin glycosides were present in all parts of the plant and fruit, while caffeic acid was only found in the fruit peels. Any correlation between plant components and inhibition of the G3 and C1 strains was not apparent, although all the powders were variably effective. Tomato leaf was the most effective powder in all strains, and was also the highest in tomatine. S. enterica showed a minor susceptibility while B. cereus and C. albicans fungi both showed a significant growth inhibition with some of the test powders. The powders inhibited growth of the pathogens without affecting beneficial lactobacilli found in the normal flora of the vagina. CONCLUSIONS: The results suggest that powders prepared from tomato leaves, stems, and green tomato peels and to a lesser extent from peels from yellow and red tomatoes offer potential multiple health benefits against infections caused by pathogenic protozoa, bacteria, and fungi, without affecting beneficial lactobacilli that also reside in the normal flora of the vagina.


Asunto(s)
Antitricomonas/farmacología , Antitricomonas/uso terapéutico , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Solanum lycopersicum/química , Solanum lycopersicum/parasitología , Tricomoniasis/tratamiento farmacológico , Animales , California , Gatos/parasitología , Bovinos/parasitología , Femenino , Frutas/química , Humanos , Masculino , Hojas de la Planta/química , Tallos de la Planta/química , Trichomonas/efectos de los fármacos
4.
Parasitol Res ; 120(9): 3263-3272, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34342682

RESUMEN

In recent years, increasing attention has been paid to the novel drug delivery systems to reduce the dose of the drug and avoid side effects. Metronidazole has been used for many years in the treatment of anaerobic bacterial and protozoal infections. Nanolactoferrin, a newly developed antibacterial agent originated from lactoferrin, is applied both as an active therapeutic and a drug nanocarrier. The present study describes the development and characterization of metronidazole-loaded lactoferrin nanoparticles (nano-MTZ) as well as reports their antitrichomonal activity on Trichomonas gallinae, the protozoal causative agent of pigeon trichomoniasis. The activity of the nano-MTZ is compared with the regular metronidazole formulation (MTZ) under in vitro and in vivo conditions. Additionally, cytotoxicity of the nano-MTZ to fibroblast cell line and possible hepatotoxicity in treated pigeons were evaluated. Nano-MTZ was prepared based on the thermal treatment method and the average size and surface charge of the dispersion were 30.6 nm and - 44.6 mv, respectively. No significant cytotoxicity was noted for the nano-MTZ in comparison to the MTZ. Loading efficiency in nano-MTZ was calculated as 55%. In vitro susceptibility results demonstrated 24 h 90% lethal concentration values of 4.23 and 6.64 µg/mL for MTZ and nano-MTZ, respectively. Oral treatment of the pigeons experimentally infected with T. gallinae resulted in the earlier eradication of the infection in the nano-MTZ-treated pigeons. No adverse effects on the liver function have been observed for the nano-MTZ. These findings suggest that nanolactoferrin is a promising platform for the development of novel MTZ formulations with improved antitrichomonal activity.


Asunto(s)
Antitricomonas/uso terapéutico , Columbidae/parasitología , Lactoferrina , Metronidazol/uso terapéutico , Nanopartículas , Tricomoniasis , Animales , Tricomoniasis/tratamiento farmacológico , Tricomoniasis/veterinaria
5.
Int J STD AIDS ; 32(1): 89-91, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33121364

RESUMEN

Metronidazole desensitization is recommended in patients with trichomoniasis and history of an allergic reaction to metronidazole due to presumed cross reactivity with tinidazole and lack of reliably safe and effective alternative therapies. We report our experiences in a patient with persistent trichomoniasis who failed to complete metronidazole desensitization due to a burning sensation over her whole body and pruritus but was later successfully desensitized to tinidazole without experiencing any adverse effects.


Asunto(s)
Antitricomonas/farmacología , Antitricomonas/uso terapéutico , Metronidazol/efectos adversos , Tinidazol/uso terapéutico , Tricomoniasis/tratamiento farmacológico , Trichomonas vaginalis/efectos de los fármacos , Adulto , Resistencia a Medicamentos , Femenino , Humanos , Hipersensibilidad , Resultado del Tratamiento , Trichomonas vaginalis/aislamiento & purificación
6.
Curr Med Sci ; 39(5): 836-842, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31612405

RESUMEN

This study aims to analyze the clinical use of ornidazole injection at the post-marketing stage by centralized hospital monitoring system method, and investigate its widespread use in patients, in order to regulate and guide the rational drug use, improve the drug specificity and provide a basis for drug therapy. The study adopts a prospective, multi-center, large sample size, centralized hospital monitoring system. We selected five leading hospitals in Hubei province, and observed the inpatients who received the ornidazole injection from July 1, 2015 to October 31, 2015. The basic information of patients was recorded, as well as the drug use and adverse events. The statistical analysis was performed based on these data. A total of 4396 individuals were enrolled in this study, most of them were middle-aged female patients and the ornidazole injection was mainly used as prophylactic prior to surgery to prevent the infections, and surgical treatment of anaerobic infections, abdominal infections and pelvic infections. The irrational drug use existed mainly in the prescribing and administration process, including unreasonable dosing frequency, rapid intravenous drip speed and extended duration of drug use. Eleven cases of adverse reactions were collected during the monitoring, incidence rate of adverse reactions was 2.5‰; adverse drug reactions occurred within 30 min. The study results fully reflected the usage of ornidazole injection in the real world. Based on the study, we calculated the adverse reaction incidence of ornidazole and identified the risk factors which may affect the safety of ornidazole injection. Study results strongly recommend that the manufacturers should publish standards for inpatient use and doctors should prescribe with caution accordingly.


Asunto(s)
Antitricomonas/uso terapéutico , Monitoreo de Drogas/tendencias , Sistemas de Medicación en Hospital/estadística & datos numéricos , Ornidazol/uso terapéutico , Profilaxis Pre-Exposición/estadística & datos numéricos , Vigilancia de Productos Comercializados/tendencias , Adulto , Anciano , Antitricomonas/efectos adversos , Antitricomonas/provisión & distribución , Femenino , Humanos , Inyecciones , Pacientes Internos , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/prevención & control , Ornidazol/efectos adversos , Ornidazol/provisión & distribución , Infección Pélvica/prevención & control , Pautas de la Práctica en Medicina/estadística & datos numéricos , Profilaxis Pre-Exposición/métodos , Estudios Prospectivos , Factores de Riesgo
8.
Turkiye Parazitol Derg ; 42(2): 168-170, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30070647

RESUMEN

We aimed to demonstrate that Pentatrichomonas hominis may also be an agent, although rare, in diarrheal episodes. Stool samples were first examined macroscopically and microscopically during routine parasitological examinations. Samples were then evaluated by Native-Lugol and formol-ethyl acetate centrifugation method. To exclude other pathogenic bacterial agents, a bacteriological culture method was applied. Samples were evaluated using a qualitative immunochromatographic test kit for rotavirus and adenovirus. We presented three cases of 77-year-old and 10-year-old male and 9-year-old female patients. Cases 1 and 2 were admitted to the hospital with complaints of diarrhea, abdominal pain, and weakness in July 2013. Leukocytes and active P. hominis trophozoites were detected. No bacterial and other parasitic and viral agents were found in their stool specimens. Oral metronidazole treatments were administered to the patients. In Case 3, P. hominis trophozoites were detected in the cellophane band in the plastic locked bag which could survive for 48 hduring a field survey in May 2012. Case 3 was contacted and advised to visit a pediatrician. P. hominis is a rare parasitic zoonosis, and we believe that it should not be ignored among diarrheal agents.


Asunto(s)
Enfermedades Gastrointestinales/diagnóstico , Tricomoniasis/diagnóstico , Trichomonas/aislamiento & purificación , Administración Oral , Anciano , Animales , Antitricomonas/uso terapéutico , Niño , Diagnóstico Diferencial , Diarrea/parasitología , Femenino , Enfermedades Gastrointestinales/tratamiento farmacológico , Enfermedades Gastrointestinales/parasitología , Humanos , Masculino , Metronidazol/uso terapéutico , Tricomoniasis/tratamiento farmacológico , Tricomoniasis/parasitología
10.
Int J STD AIDS ; 29(8): 825-827, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29393008

RESUMEN

This study presents a case report of a female patient with symptomatic refractory Trichomonas vaginalis infection who was not able to clear her infection with high-dose oral metronidazole, oral tinidazole, intra-vaginal zinc sulfate, intra-vaginal metronidazole, intra-vaginal tinidazole, and intra-vaginal boric acid. She was unable to tolerate intra-vaginal paromomycin. A combination of intravenous metronidazole, oral tinidazole liquid suspension, and intra-vaginal boric acid for 14 days subsequently achieved a complete symptomatic and laboratory cure.


Asunto(s)
Antiprotozoarios/administración & dosificación , Antitricomonas/administración & dosificación , Ácidos Bóricos/administración & dosificación , Metronidazol/administración & dosificación , Tinidazol/administración & dosificación , Vaginitis por Trichomonas/tratamiento farmacológico , Trichomonas vaginalis/efectos de los fármacos , Administración Intravaginal , Administración Intravenosa , Adulto , Antiprotozoarios/uso terapéutico , Antitricomonas/uso terapéutico , Ácidos Bóricos/uso terapéutico , Femenino , Derivación Gástrica , Humanos , Metronidazol/uso terapéutico , Tinidazol/uso terapéutico , Resultado del Tratamiento , Trichomonas vaginalis/aislamiento & purificación
13.
Rev Esp Enferm Dig ; 109(1): 64-65, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28100059

RESUMEN

The authors present the case of a 32-year-old Caucasian male, engineer, who was submitted to a colonoscopy after a presumptive diagnosis of ulcerative colitis. The patient referred an acute bloody and mucous diarrhea, lasting for three weeks, with no fever or rectal tenesmus. Stool studies were negative. During the procedure, colonic segments with continuous hyperemic and exudative mucosa, with small papules with apical ulcers and erosions, were observed.


Asunto(s)
Colitis Ulcerosa/etiología , Entamoeba histolytica , Entamebiasis/complicaciones , Adulto , Antitricomonas/uso terapéutico , Colitis Ulcerosa/psicología , Entamebiasis/tratamiento farmacológico , Entamebiasis/parasitología , Humanos , Masculino , Metronidazol/uso terapéutico
14.
Cutan Ocul Toxicol ; 36(3): 294-296, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27780370

RESUMEN

BACKGROUND: Fixed drug eruption (FDE) is a special variant of drug reaction seen on skin or mucous membrane, and typically recurs at the same location. Ornidazole-induced FDE cases have been reported extremely rare. CASE: The 48-year-old female patient was diagnosed for ornidazole-induced fixed drug reaction on the sole. The patient's history revealed that the lesion occurred for the third time in the last 6 months and she was administered ornidazole tablet 3 times by the gynecologist for genitourinary tract infection. CONCLUSION: This report presents a case of fixed drug reaction located at the sole induced by ornidazole use and a literature review.


Asunto(s)
Antitricomonas/efectos adversos , Erupciones por Medicamentos/etiología , Ornidazol/efectos adversos , Antitricomonas/uso terapéutico , Erupciones por Medicamentos/patología , Femenino , Humanos , Persona de Mediana Edad , Ornidazol/uso terapéutico , Piel/efectos de los fármacos , Piel/patología , Infecciones Urinarias/tratamiento farmacológico
15.
Int J STD AIDS ; 27(10): 906-8, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-26384945

RESUMEN

Trichomonas vaginalis is a sexually transmitted protozoan infection resulting in vulvo-vaginitis and altered vaginal discharge in symptomatic women. Trichomoniasis has been implicated in causing adverse pregnancy outcomes such as low birth weight and pre-term labour. Metronidazole is the recommended first-line treatment for trichomonal infection. Other nitroimidazoles, such as tinidazole, are used as alternative regimens with similar activity but at a greater expense. Treatment failure usually represents patient non-compliance or re-infection, although metronidazole resistance has previously been documented. Antimicrobial susceptibility testing for T. vaginalis is currently not available in the UK. Patients with disease unresponsive to first-line treatments pose a major challenge, as therapeutic options are limited. We present the case of a patient with presumed resistant infection during pregnancy, and the additional treatment issues that this presented.


Asunto(s)
Antitricomonas/uso terapéutico , Metronidazol/uso terapéutico , Complicaciones Parasitarias del Embarazo/tratamiento farmacológico , Tinidazol/uso terapéutico , Vaginitis por Trichomonas/tratamiento farmacológico , Trichomonas vaginalis/aislamiento & purificación , Resistencia a Medicamentos , Femenino , Humanos , Embarazo , Complicaciones Parasitarias del Embarazo/diagnóstico , Resultado del Embarazo , Resultado del Tratamiento , Vaginitis por Trichomonas/diagnóstico , Trichomonas vaginalis/efectos de los fármacos
16.
Cutan Ocul Toxicol ; 33(4): 337-8, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24938451

RESUMEN

Baboon syndrome is a special form of systemic contact dermatitis to systemic or local administration of contact allergens. Baboon syndrome without known previous cutaneous sensitisation was also described as drug-related baboon syndrome or symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). The major drugs causing SDRIFE was beta-lactam antibiotic such as amoxicillin and ampicillin. We report a case of 16-year-old woman who developed pruritic eruptions after oral metronidazole treatment for diarrhea. She was diagnosed SDRIFE according to her clinical and histopathological findings. To our knowledge, our patient is the first case who developed SDRIFE due to metronidazole in the literature.


Asunto(s)
Antitricomonas/efectos adversos , Erupciones por Medicamentos/patología , Exantema/inducido químicamente , Metronidazol/efectos adversos , Adolescente , Antitricomonas/uso terapéutico , Nalgas/patología , Diarrea/complicaciones , Diarrea/tratamiento farmacológico , Exantema/patología , Femenino , Humanos , Metronidazol/uso terapéutico , Piel/patología
17.
Expert Rev Anti Infect Ther ; 12(6): 673-85, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24555561

RESUMEN

Trichomonas vaginalis (TV) is a common sexually transmitted infection that can cause vaginitis, cervicitis and urethritis. Persistent and recurrent TV infections are frequent in women, potentially due to the lack of routine screening recommendations for this pathogen, the chronic nature of some infections, and drug resistance. Metronidazole and tinidazole are two oral drugs that are effective against trichomoniasis. There are few alternative treatment options for persons with a metronidazole allergy or treatment failure. Most TV isolates from women with treatment failures that have been analyzed for susceptibility testing in the United States have exhibited low-level metronidazole resistance, supporting the initial use of tinidazole for patients who fail metronidazole therapy. Several non-nitroimidazole drugs and other agents have demonstrated acceptable in vitro activity or cure rates in case reports for metronidazole-resistant trichomoniasis; however, clinical trials are imperative to evaluate their efficacy as alternative therapeutic regimens for this highly prevalent infection.


Asunto(s)
Antitricomonas/uso terapéutico , Resistencia a Medicamentos , Enfermedades de Transmisión Sexual/epidemiología , Vaginitis por Trichomonas/epidemiología , Trichomonas vaginalis/fisiología , Antitricomonas/farmacología , Femenino , Humanos , Masculino , Metronidazol/farmacología , Metronidazol/uso terapéutico , Recurrencia , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Tinidazol/farmacología , Tinidazol/uso terapéutico , Insuficiencia del Tratamiento , Vaginitis por Trichomonas/diagnóstico , Vaginitis por Trichomonas/tratamiento farmacológico , Trichomonas vaginalis/efectos de los fármacos
18.
J Parasitol ; 100(3): 360-3, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24456034

RESUMEN

Trichomonas gallinae , the cause of avian trichomonosis, is most commonly found in the order Columbiformes. Racing pigeons are often treated preventively with nitro-imidazoles, which could result in the emergence of resistant isolates, and these isolates can be a threat to wildlife when exchanges occur. The sequence type of 16 T. gallinae isolates obtained from racing pigeons and 15 isolates from wild pigeons was determined based on the ITS1/5.8S rRNA/ITS2 region sequence. In addition, the resistance profiles of these isolates against 5 different nitro-imidazoles (metronidazole, dimetridazole, ronidazole, tinidazole, and carnidazole) were determined. Two different Trichomonas sequence types were isolated. Sequence type A isolates were recovered from racing and wild pigeons, in contrast to sequence type B, which was only isolated from wild pigeons. Isolates with sequence type B were all susceptible to the tested nitro-imidazoles, except for tinidazole resistance in 3 isolates. Resistance to the nitro-imidazoles was observed more frequently in isolates obtained from racing pigeons than from wild pigeons, with most isolates belonging to sequence type A. A higher percentage of the sequence type A isolated from racing pigeons, in comparison with those isolated from the wild pigeons, were resistant to the nitro-imidazoles and displayed higher mean lethal concentration (MLC) values. Two isolates belonging to sequence type A, 1 recovered from a racing pigeon and 1 from a wild pigeon, displayed a similar resistance pattern, suggesting a potential exchange of resistant isolates between racing pigeons and wild pigeons.


Asunto(s)
Antitricomonas/farmacología , Enfermedades de las Aves/parasitología , Columbidae/parasitología , Nitroimidazoles/farmacología , Tricomoniasis/veterinaria , Trichomonas/efectos de los fármacos , Animales , Animales Domésticos , Animales Salvajes , Antitricomonas/uso terapéutico , Enfermedades de las Aves/tratamiento farmacológico , Enfermedades de las Aves/transmisión , Buche de las Aves/parasitología , ADN Protozoario/química , ADN Ribosómico/química , ADN Espaciador Ribosómico/química , Reservorios de Enfermedades/veterinaria , Resistencia a Medicamentos , Dosificación Letal Mediana , Nitroimidazoles/uso terapéutico , Pruebas de Sensibilidad Parasitaria/veterinaria , Reacción en Cadena de la Polimerasa/veterinaria , ARN Protozoario/genética , ARN Ribosómico 5.8S/genética , Trichomonas/clasificación , Trichomonas/genética , Trichomonas/aislamiento & purificación , Tricomoniasis/tratamiento farmacológico , Tricomoniasis/parasitología , Tricomoniasis/transmisión
19.
Biomed Res Int ; 2013: 390920, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24073401

RESUMEN

In our presented research, we made an attempt to predict the 3D model for cysteine synthase (A2GMG5_TRIVA) using homology-modeling approaches. To investigate deeper into the predicted structure, we further performed a molecular dynamics simulation for 10 ns and calculated several supporting analysis for structural properties such as RMSF, radius of gyration, and the total energy calculation to support the predicted structured model of cysteine synthase. The present findings led us to conclude that the proposed model is stereochemically stable. The overall PROCHECK G factor for the homology-modeled structure was -0.04. On the basis of the virtual screening for cysteine synthase against the NCI subset II molecule, we present the molecule 1-N, 4-N-bis [3-(1H-benzimidazol-2-yl) phenyl] benzene-1,4-dicarboxamide (ZINC01690699) having the minimum energy score (-13.0 Kcal/Mol) and a log P value of 6 as a potential inhibitory molecule used to inhibit the growth of T. vaginalis infection.


Asunto(s)
Antitricomonas/farmacología , Antitricomonas/uso terapéutico , Cisteína Sintasa/antagonistas & inhibidores , Cisteína Sintasa/química , Simulación de Dinámica Molecular , Tricomoniasis/tratamiento farmacológico , Trichomonas/enzimología , Dominio Catalítico , Cisteína Sintasa/metabolismo , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Enlace de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas/efectos de los fármacos , Ligandos , Reproducibilidad de los Resultados , Programas Informáticos , Especificidad por Sustrato/efectos de los fármacos , Termodinámica , Trichomonas/efectos de los fármacos , Interfaz Usuario-Computador
20.
Ginecol Obstet Mex ; 81(5): 231-8, 2013 May.
Artículo en Español | MEDLINE | ID: mdl-23819423

RESUMEN

BACKGROUND: In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy. OBJECTIVE: To compare the effectiveness of two combinations of three oral antimicrobial drugs in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis. MATERIAL AND METHOD: Aclinical, random, comparative, double-blind study included 50 patients assisting to infectology consult with diagnosis of mixed cervical-vaginal infection. Patients were divided into two groups: Group A (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and azithromycin 250 mg; group B (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and clindamycin 312.5 mg. Patients of both groups received two tablets twice p.o. for one day. Cultures were performed to corroborate the diagnosis and then to demonstrate effectiveness of the schemes studied. For the analysis of the data we used measures of central tendency, dispersion and inferential statistics for comparison of proportions by c2 and Fisher's exact tests with a significance level of p < 0.05. RESULTS: All patient got clinical cure; however, regarding the microbiologic eradication a positive case was identified in group A, requiring rescue treatment. The compliance in both groups was of 100%. In both groups, statistical analysis did not show significant differences. Three patients in group A had mild adverse effects. Patients mean age was 33.4 +/- 5.3 years. CONCLUSIONS: Both treatments showed similar effectiveness against mixed cervical-vaginal infections. Microbiological efficacy was of 96% and 100% in group A and B, respectively, besides, scheme of group B was better tolerated.


Asunto(s)
Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Antitricomonas/uso terapéutico , Azitromicina/uso terapéutico , Clindamicina/uso terapéutico , Fluconazol/uso terapéutico , Infecciones por Mycoplasma/tratamiento farmacológico , Tinidazol/uso terapéutico , Enfermedades del Cuello del Útero/tratamiento farmacológico , Enfermedades del Cuello del Útero/microbiología , Enfermedades Vaginales/tratamiento farmacológico , Enfermedades Vaginales/microbiología , Adulto , Infecciones por Chlamydia/tratamiento farmacológico , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA